




19TH ANNUAL CHILD HEALTH RESEARCH DAYS
Outcomes in Child Health



October 25 + 26, 2023 | RBC Convention Centre, Winnipeg, Manitoba

Abstract Submission Form

CHR D 2023: Abstract Submission Form

Submitter Name

Saeid Maghsoudi

Presenter Name

Saeid Maghsoudi

Presenter Status

PhD Student

Research Category

Basic Science

Role in the project

Design
Perform Experiments
Analyze Data
Write Abstract

Title

Discovery of A Novel and Selective Adenylyl Cyclase Isoform 6 Activator: A Potential Therapeutic Option for Pulmonary Hypertension in the Neonates

Background

Persistent pulmonary hypertension of the newborn (PPHN) is a failure of pulmonary vascular relaxation after birth. Adenylyl cyclase (AC) mediates vasorelaxation and is crucial drug target. AC isoforms 3, 6, 7 and 9 are expressed in neonatal pulmonary arteries (PA); AC6 is predominant. AC6 is inhibited due to S-nitrosylation in PPHN PA, and in PA myocytes exposed to hypoxia.

Objective

Analyze the activity of a series of novel forskolin derivatives against AC isoforms 3, 5, 6, 7, and 9.

Methods

Through homology modelling, the AC6 structural model was generated. Functions of forskolin-interacting residues of the AC6 allosteric pocket were discovered by ligand docking and using site-directed mutagenesis. HEK293T cells stably overexpressing AC isoforms 3, 5, 6, 7 or 9 were cultured in normoxia (21% O₂) or hypoxia (10% O₂) for 72 hours, or challenged with nitroso donor S-nitrosocysteine (CSNO), followed by AC activity assay. Forskolin-dependent real-time cAMP generation was measured using a live-cell cAMP biosensor. A library of forskolin derivatives was synthesized and screened against all AC isoforms. Dose-response testing was performed for compounds showing AC6 selectivity.

Results

Hypoxia and CSNO both decreased the catalytic activity of AC6 due to S-nitrosylation. Residues T500, N503, and S1035 interact with forskolin; mutation of T500, N503, or S1035 diminished forskolin-stimulated AC activity relative to AC6WT. Forskolin site mutants were not further inhibited by hypoxia or CSNO. cAMP dynamics showed forskolin unresponsiveness of all mutants. Among forskolin derivatives tested, forskolin 1 α , 9 α -carbonate offered relatively selective activation of AC6.

Conclusion

Although hypoxia inhibits AC6, forskolin can stimulate catalytic activity of AC6 under hypoxic conditions. The hypoxia inhibitory mechanism does not involve amino acids that interact with forskolin. Selective AC6 reactivation is a potential therapeutic target in PPHN. The C1 carbamate derivative of forskolin may interact selectively with the AC6 FSK binding site.

Authors

Name	Email	Role	Profession
Saeid Maghsoudi	maghsous@myumanitoba.ca	Presenting Author	Graduate
Alex Pritchard	pritchaa@myumanitoba.ca	Co Author	Graduate
Vikram Bhatia	Vikram.Bhatia@umanitoba.ca	Co Author	Other
Martha Hinton	Martha.Hinton@umanitoba.ca	Co Author	Other
Prashen Chelikani	Prashen.Chelikani@umanitoba.ca	Co Author	Full Professor
John Sorensen	John.Sorensen@umanitoba.ca	Co Author	Full Professor
Shyamala Dakshinamurti	Shyamala.Dakshinamurti@umanitoba.ca	Co Author	Full Professor